FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trial Compass continues to advance ...
Compass Pathways has navigated to another successful midphase readout, linking its psilocybin therapy and psychological support to improvements in post-traumatic stress disorder (PTSD) in a small ...
These data represent one of the largest clinical development programs to date for adults living with PTSD and a significant development in a therapy area that hasn’t seen a new approval for a ...
According to the letter, the application could not be approved due to lack of substantial efficacy from the submitted studies. The Food and Drug Administration (FDA) has issued a Complete Response ...
Many people have interpreted as a setback the “no” vote by an advisory committee to the Food and Drug Administration on Lykos Therapeutics’ new drug application for MDMA-assisted psychotherapy for ...
The results will be used to seek FDA approval of MDMA, also known as ecstasy, as a treatment for post-traumatic stress disorder. Treating post-traumatic stress disorder (PTSD) with a combination of ...
Researchers discovered that PTSD may be driven by excess GABA from astrocytes, not neurons. This chemical imbalance disrupts the brain’s ability to forget fear. A new drug, KDS2010, reverses this ...
A lab at the University of Idaho will use a Department of Defense grant to develop machine learning models that might be able ...
When I was in medical school, senior physicians would frequently usher a group of us students into a patient’s room so we might hear them tell the story of their illness. It seemed that the more ...
LONDON & NEW YORK, January 07, 2026--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results